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Abstract
Ambrisentan in 22 patients with pulmonary hypertension diagnosed during exercise (ePH) improved pulmonary hemodynamics;
however, there was only a trend toward increased maximum oxygen uptake (VO2max) secondary to decreased maximum exercise
systemic oxygen extraction (Ca-vO2). We speculate that improved pulmonary hemodynamics at maximum exercise ‘‘unmasked’’ a
pre-existing skeletal muscle abnormality.
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Pulmonary hypertension diagnosed during exercise (ePH) is
increasingly recognized as a clinically relevant and early
form of pulmonary arterial hypertension (PAH);1 however,
ePH is not universally accepted as a disease worthy of diag-
nosis or treatment.2,3 Our group has recently completed an
open label study of the safety and efficacy of ambrisentan
in patients with ePH,4 showing that despite improvement
in pulmonary hemodynamics and functional status, there
was only a trend toward increased maximum oxygen
uptake (VO2max). In the present report, we aimed to explain
this discrepancy by examining the Fick principle determin-
ants of VO2max of 22 patients evaluated in the aforemen-
tioned clinical trial.
The study was approved by Partners Human Research
Committee, as previously reported.4 ePH was defined as
mean pulmonary artery pressure (mPAP)> 30mmHg, pul-
monary arterial wedge pressure (PAWP)< 20mmHg, and
pulmonary vascular resistance (PVR)> 1 Wood Units
(WU) at peak exercise, in the absence of resting PAH.1 All
participants underwent invasive cardiopulmonary exercise
testing at baseline and at six-month follow-up.4 In the pre-
sent report, we analyzed cardiac output (CO), systemic
oxygen extraction (Ca-vO2), and delivery (DO2) based on
Fick principle determinants of VO2max. In an effort to
adjust for anemia (a known side effect of ambrisentan),5
peak Ca-vO2 was corrected for hemoglobin (Hb) levels.
Data are presented as n, n (%) or mean standard devi-
ation. The distribution of continuous variables was evalu-
ated using Shapiro–Wilk test. Comparisons between
parameters obtained at baseline and during follow-up were
performed using paired t test or Wilcoxon signed-rank test,
as appropriate for distribution. P< 0.05 was considered
statistically significant. The statistical analyses were per-
formed using SPSS software, Version 19 (IBM Company,
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Armonk, NY, USA) and Stata 14 (Stata Corp LP, College
Station, TX, USA).
Of the 30 enrolled patients, 22 completed the study proto-
col. Eight individuals were excluded from the study due to
adverse side effects, as previously described.4 The mean age
was 58.6 9.9 years (8 men, 14 women). At 24 weeks and at
peak exercise, there was reduction of mPAP and PVR while
CO was improved. Peak systemic vascular resistance (SVR)
was decreased. While there was improvement in peak DO2
(Fig. 1), there was only a trend toward increased VO2max %
predicted. No difference in VO2 at the anaerobic threshold
(% VO2max predicted) (baseline¼ 45.0 14.1%, 24 week-
s¼ 47.5 16.2%; P¼ 0.36) or maximum work rate was
observed. Peak Ca-vO2 (Fig. 1), Hb (baseline¼ 14.0
1.3 g/dL, 24 weeks¼ 13.4 1.7 g/dL; P¼ 0.005), and arterial
oxygen content (CaO2) were decreased. After Ca-vO2 was
corrected for Hb, it remained lower compared to the base-
line value. There was no difference in maximum exercise
arterial pH, arterial carbon dioxide partial pressure, arterial
oxygen partial pressure (PaO2), arterial oxygen saturation
(SaO2), alveolar–arterial oxygen tension difference, mixed-
venous pH, mixed-venous carbon dioxide partial pressure,
and mixed-venous oxygen partial pressure, while mixed-
venous oxygen saturation was increased at follow up
(Table 1).
A sub-analysis of eight patients with parenchymal
lung disease did not demonstrate a deleterious effect on
PaO2 (baseline¼ 70.1 18.2mmHg, 24 weeks¼ 69.7
18.3mmHg; P¼ 0.88) and/or SaO2 (baseline¼ 91.6 3.8%,
24 weeks¼ 91.5 4.2%; P¼ 0.86). No treatment-related
changes of pulse oxygen saturation after 6-min walk test
were observed in the eight patients with parenchymal lung
disease (baseline¼ 91.88 5.25%, 24 weeks¼ 90.67
3.72%; P¼ 0.08).
The principal finding of the current report is that max-
imum exercise Ca-vO2 decreased in ePH patients treated
with ambrisentan, blunting a potential rise in VO2max due
to improved pulmonary hemodynamics and DO2. This may
be important for clinical trial design in pulmonary vascular
disease. If the endpoint of the clinical trial is a non-invasive
VO2max alone, improvements in exercise pulmonary hemo-
dynamics may be masked by the confounding effects of
impaired Ca-vO2.
Fig. 1. (a) Oxygen delivery (DO2) and (b) oxygen extraction (Ca-vO2) at peak exercise.
Table 1. Peak exercise hemodynamics and gas-exchange variables.
Baseline Week 24 P
mPAP (mmHg) 38.0 6.6 33 5.2 0.001
PVR (WU) 2.3 0.9 1.4 0.5 0.0002
CO (L/min) 10.9 3.8 13.2 3.8 0.0001
SVR (dynes/s/cm–5) 836.7 241.8 649.4 200.1 0.0001
DO2 (mL/min) 2075 823 2344 875 <0.001
VO2max (% predicted) 75.0 19.3 79.4 21.4 0.07
VO2max (mL/min) 1430 549.99 1512 615.15 0.03
WR (watts) 109.4 65.50 111.7 58.67 0.68
Ca-vO2 (mL/dL) 12.5 2.3 11.1 2.3 0.0001
Ca-vO2/Hb (mL/dL) 0.89 0.12 0.83 0.15 0.003
CaO2 (mL/dL) 18.7 2.4 17.4 2.6 <0.001
pH 7.37 0.04 7.36 0.05 0.38
PaCO2 (mmHg) 34.1 4.4 34.4 5.9 0.81
PaO2 (mmHg) 82.8 18.5 79.4 16.8 0.15
SaO2 (%) 94 3 94 4 0.39
PAaO2 (mmHg) 34.7 16.0 36.7 14.3 0.53
pHv 7.26 0.05 7.26 0.05 0.55
PvCO2 (mmHg) 58.7 7.6 57.6 6.9 0.38
PvO2 (mmHg) 25.5 3.4 26.4 3.3 0.25
SvO2 (%) 33 8 36 8 0.04
Data are presented as n, mean standard deviation.
mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance;
CO, cardiac output; SVR, systemic vascular resistance; DO2, oxygen delivery;
VO2, oxygen uptake; WR, work rate; Ca-vO2, systemic oxygen extraction; Hb,
hemoglobin; CaO2, arterial oxygen content; PaCO2, arterial carbon dioxide
partial pressure; PaO2, arterial oxygen partial pressure; SaO2, arterial oxygen
saturation; PAaO2, alveolar–arterial oxygen tension difference; pHv, mixed-
venous pH; PvCO2, mixed-venous carbon dioxide partial pressure; PvO2,
mixed-venous oxygen partial pressure; SvO2, mixed-venous oxygen saturation.
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One possible explanation for our observations is the pres-
ence of systemic arteriolar endothelial dysfunction in ePH
that is unmasked by its treatment. Systemic arterial endo-
thelial dysfunction may exist in PAH due to a deficit of
vasodilators such as nitric oxide and prostacyclin, and over-
expression of vasoconstrictors, such as thromboxane A2 and
endothelin-1.6 In the human, Peled et al.7 evaluated endo-
thelial dysfunction, reporting lower post occlusion brachial
artery flow- mediated dilation in PAH patients when com-
pared to healthy controls. During exercise, under normal
circumstances, regional blood supply to skeletal muscle is
progressively shifted away from other organ beds such as
the gut and kidney toward exercising muscle and within the
muscle toward oxidative fibers.8 Increased plasma endothe-
lin-1 during exercise may contribute to such redistribution
of blood flow.9,10 In the rat, the arteriolar resistors serving
fast-twitch glycolytic skeletal muscle fibers are endothelin-1
sensitive,11 so it is possible their blockade by ambrisentan
allows disproportionate perfusion of fast-twitch glycolytic
fibers, depriving slow-twitch muscle fibers and their mito-
chondria of blood flow and DO2. This is a critical observa-
tion, since slow-twitch fibers have a greater influence on
VO2max when compared with fast-twitch fibers.
12 In the
hypoxic rat, skeletal muscle capillary blood flow is increased
by ambrisentan.13 In another study, bosentan increased flow
mediated vasodilation in PAH.14 Our data suggest that if
ET-1 blockade increases skeletal muscle blood flow at peak
exercise in PAH, it does so indiscriminately, without prefer-
ential perfusion of the slow-twitch oxidative muscle
fiber. Furthermore, the lowered SVR after treatment with
ambrisentan suggests that inappropriate systemic vasodila-
tion secondary to the drug might have adversely affected
muscle oxygen uptake and utilization.
Abnormal systemic microcirculatory structure may also
underlie our observations. Lower capillary density within
the skeletal muscle impairs muscle DO2, despite normal
CO response and estimated DO2 in PAH.
15 Potus et al.16
suggested skeletal muscle microvessel loss associated with
downregulation of microRNA-126 correlates with poor
exercise tolerance in PAH. In a manner similar to systemic
arteriolar endothelial dysfunction, changes in vessel struc-
ture combined with drug-induced increased blood flow to
the limb skeletal muscle, may result in mismatch of perfu-
sion and oxidative metabolism, and impaired Ca-vO2.
It is also possible that intrinsic abnormality of skeletal
muscle mitochondrion exists in PAH and is unmasked after
its treatment with ambrisentan. The hallmark of a mito-
chondrial myopathy in the human is impaired Ca-vO2 at
peak exercise.17 Previous studies have shown that impaired
exercise capacity in PAH is related to the presence of cellular
signaling networks that prompt muscle proteolysis and
downregulate protein synthesis, and low expression of pro-
teins that regulate mitochondrial fusion in skeletal muscle,
an important contributing factor to skeletal muscle atrophy
and excitation-contraction impairment in patients with
PAH.18 Malenfant et al. studied the proteomic signature
of skeletal muscle in PAH and demonstrated downregula-
tion of proteins related to mitochondrial structure and func-
tion, with lower expression of oxidative enzymes and higher
expression of glycolytic enzymes in PAH.19 Therefore, it is
possible that intrinsic mitochondrial dysfunction is asso-
ciated with impaired Ca-vO2 in our population and is exag-
gerated when DO2 is improved due to therapy.
Recently, the ERS statement in pulmonary hemo-
dynamics during exercise20 defined ePH by the presence of
mPAP< 25mmHg at rest and >30mmHg at peak exercise,
and total pulmonary resistance (TPR)> 3WU. In a similar
way, our definition includes indices of pressure and resist-
ance and, therefore, we do not think the implementation of
the ERS definition to our population would have changed
our results.
In conclusion, we speculate that improved pulmonary
hemodynamics and CO at maximum exercise ‘‘unmasked’’
a pre-existing skeletal muscle abnormality, which could
include systemic vascular and/or mitochondrial structure
or function. We suggest the following analogy: if improved
DO2 after ambrisentan is a ‘‘new engine,’’ and the peripheral
problem is the ‘‘old car;’’ placing a ‘‘new engine in an old
car’’ would allow us to find the other parts of the car that do
not work properly.
Our observations are limited by the small number of
patients and the single-center design of the clinical trial.
Also, the analysis was restricted to the per-protocol popu-
lation and, therefore, can lead to biased results that favored
inclusion of patients whose pulmonary hemodynamics
improved. However, this is the first study, to our knowledge,
to describe impaired exercise Ca-vO2 after treatment of ePH
with a pulmonary vasodilator. Impairment or unmasking of
abnormal Ca-vO2 during exercise may contribute to exer-
tional intolerance in ePH and may represent a confounding
variable for clinical trials whose outcomes include the func-
tional status of the patient. Multicenter placebo-controlled
randomized clinical trials are warranted to confirm our find-
ings in ePH and document the influence of pulmonary vaso-
dilators on exercise capacity, including VO2max and its Fick
principle determinants.
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